← Back to Search

Online Intervention for Gestational Diabetes Postpartum Care (SUNRISE Trial)

N/A
Waitlist Available
Led By Susan D Brown, PhD
Research Sponsored by University of California, Davis
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age: 18 years and older
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4-52 weeks postpartum
Awards & highlights

SUNRISE Trial Summary

This trial tests components of an online intervention to help women with GDM get postpartum screening and programs for diabetes prevention. It mixes standard health info with motivational and logistical help. It uses a randomized factorial study design.

Who is the study for?
This trial is for pregnant individuals aged 18 or older with gestational diabetes, who speak English and are in contact with the Kaiser Permanente Northern California's perinatal service. It excludes those currently hospitalized, with pregnancy loss, prior requests to avoid research invites, eating disorders, or pre-pregnancy diabetes.Check my eligibility
What is being tested?
The study tests a digital health program designed to encourage postpartum screening and lifestyle changes for diabetes prevention. Participants receive standard health info plus up to four additional components like motivational interviewing and action planning using an interactive online platform.See study design
What are the potential side effects?
Since this trial involves information-based interventions rather than medications, traditional side effects are not expected. However, participants may experience stress or anxiety related to receiving health risk information.

SUNRISE Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.

SUNRISE Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4-52 weeks postpartum
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4-52 weeks postpartum for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Completion of recommended postpartum diabetes screening.
Secondary outcome measures
Completion of any recommended postpartum diabetes screening test.
Uptake of a lifestyle program for diabetes prevention.

SUNRISE Trial Design

16Treatment groups
Experimental Treatment
Group I: Condition 9Experimental Treatment4 Interventions
Standard health message + TRI + MI+ AP
Group II: Condition 8Experimental Treatment2 Interventions
Standard health message + VA
Group III: Condition 7Experimental Treatment3 Interventions
Standard health message + VA + AP
Group IV: Condition 6Experimental Treatment3 Interventions
Standard health message + VA + MI
Group V: Condition 5Experimental Treatment4 Interventions
Standard health message + VA + MI+ AP
Group VI: Condition 4Experimental Treatment3 Interventions
Standard health message + VA + TRI
Group VII: Condition 3Experimental Treatment4 Interventions
Standard health message + VA + TRI + AP
Group VIII: Condition 2Experimental Treatment4 Interventions
Standard health message + VA + TRI + MI
Group IX: Condition 16Experimental Treatment1 Intervention
Standard health message
Group X: Condition 15Experimental Treatment2 Interventions
Standard health message + AP
Group XI: Condition 14Experimental Treatment2 Interventions
Standard health message + MI
Group XII: Condition 13Experimental Treatment3 Interventions
Standard health message + MI+ AP
Group XIII: Condition 12Experimental Treatment2 Interventions
Standard health message + TRI
Group XIV: Condition 11Experimental Treatment3 Interventions
Standard health message + TRI + AP
Group XV: Condition 10Experimental Treatment3 Interventions
Standard health message + TRI + MI
Group XVI: Condition 1Experimental Treatment5 Interventions
Standard health message + VA + TRI + MI+ AP

Find a Location

Who is running the clinical trial?

University of California, DavisLead Sponsor
910 Previous Clinical Trials
4,704,991 Total Patients Enrolled
Kaiser Foundation Research InstituteOTHER
27 Previous Clinical Trials
19,296 Total Patients Enrolled
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
2,356 Previous Clinical Trials
4,313,066 Total Patients Enrolled

Media Library

Condition 7 Clinical Trial Eligibility Overview. Trial Name: NCT05752292 — N/A
Gestational Diabetes Research Study Groups: Condition 7, Condition 13, Condition 11, Condition 15, Condition 10, Condition 5, Condition 6, Condition 9, Condition 1, Condition 12, Condition 3, Condition 2, Condition 4, Condition 8, Condition 14, Condition 16
Gestational Diabetes Clinical Trial 2023: Condition 7 Highlights & Side Effects. Trial Name: NCT05752292 — N/A
Condition 7 2023 Treatment Timeline for Medical Study. Trial Name: NCT05752292 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is registration for this investigation still open?

"The clinical trial's details on clinicialtrials.gov suggest this study is no longer recruiting individuals. First posted on the 1st of March 2023 and last edited 28th February, there are nevertheless 1401 other studies actively accepting patients at present."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Study to Understand Risk Information to Support and Empower
2023. "Study to Understand Risk Information to Support and Empower". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05752292.
All > Diabetes
~1143 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top